|
HS Code |
741966 |
| Iupac Name | (2S,4R)-1-[(tert-Butoxy)carbonyl]-4-methylpyrrolidine-2-carboxylic acid |
| Molecular Formula | C11H19NO4 |
| Molecular Weight | 229.273 g/mol |
| Appearance | Solid (Typical, but can vary based on purity and preparation) |
| Melting Point | Data may vary; specific values require experimental determination |
| Boiling Point | Data may vary; typically determined under specific conditions |
| Solubility | Solubility characteristics can vary with solvents; often sparingly soluble in water, more soluble in organic solvents like dichloromethane |
| Polarity | Moderate polarity due to the presence of carbonyl and carboxylic acid groups |
| Chirality | Chiral compound with (2S,4R) configuration |
| Stability | Stable under normal conditions, but sensitive to strong acids, bases, and high temperatures |
As an accredited (2S,4R)-1-[(Tert-Butoxy)Carbonyl]-4-Methylpyrrolidine-2-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of (2S,4R)-1-[(Tert - Butoxy)Carbonyl]-4 - Methylpyrrolidine - 2 - Carboxylic Acid in sealed, chemical - resistant packaging. |
| Shipping | (2S,4R)-1-[(Tert - Butoxy)Carbonyl]-4 - Methylpyrrolidine - 2 - Carboxylic Acid is shipped in well - sealed containers, protected from moisture and heat. Shipment adheres to chemical transport regulations, ensuring safe transit. |
| Storage | (2S,4R)-1-[(Tert - Butoxy)Carbonyl]-4 - Methylpyrrolidine - 2 - Carboxylic Acid should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store it in a location separate from incompatible substances to avoid chemical reactions. |
In automated solid-phase peptide synthesizers executing Boc-protection strategies on aminomethyl polystyrene or PAM resins, incorporation of (2S,4R)-1-[(tert-butoxy)carbonyl]-4-methylpyrrolidine-2-carboxylic acid (Boc-4-MePro-OH) targets the introduction of a sterically constrained proline surrogate into pharmacologically active sequences. Pre-activation of the carboxylic acid terminus is performed with HBTU (O-benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate) in anhydrous DMF at 0–5 °C, using 0.5 M DIPEA as the tertiary base, and the activated species is immediately transferred to the resin under low-shear overhead stirring in jacketed reaction vessels with internal temperature probes maintaining 22 ± 2 °C. The addition ratio is set at 2.5 to 5.0 molar equivalents of Boc-4-MePro-OH relative to resin substitution sites—determined by a quantitative Fmoc or Boc loading assay compliant with Ph. Eur. 2.2.46—while 0.1–0.5 mmol/g substitution levels on a 1% crosslinked polystyrene matrix are standard for sequences exceeding ten residues. Double coupling protocols with 60–120 min recirculation intervals are mandatory because the 4-methyl substituent elevates steric hindrance during amide bond formation, and residual free amine is monitored by a modified Kaiser test (ninhydrin-based, absorbance at 570 nm) or chloranil test for secondary amines. After chain elongation, global deprotection and cleavage from the resin with liquid HF in the presence of 10% v/v anisole at −5 °C for 45–60 min liberates the peptide acid, which is subsequently purified by reversed-phase preparative HPLC on C18 columns with 0.1% TFA/acetonitrile gradients. The entire process falls under ICH Q7 Section 19 (Active Pharmaceutical Ingredient manufacturing) and respective USP <1503> compendial requirements for synthetic peptides, with environmental, health, and safety controls aligned to REACH Annex VIII for protection/deprotection auxiliary chemicals. Terminal product types include linear and cyclic therapeutic peptides containing a (4R)-methylproline residue—such as macrocyclic NS3 protease acylsulfonamide antagonists—validated by HRMS (mass accuracy <2 ppm) and 1H‑NMR at 600 MHz to confirm >95% epimeric purity at the proline C4 center.
What Drives the Stoichiometric Window for (2S,4R)-Boc-4-Methylproline in Large-Scale Solution-Phase HCV Intermediate Couplings?Coupling of (2S,4R)-1-[(tert-butoxy)carbonyl]-4-methylpyrrolidine-2-carboxylic acid with a macrocyclic amino-ester intermediate in the manufacture of hepatitis C NS3/4A protease inhibitors resembling the grazoprevir scaffold is conducted under strict stoichiometric control to circumvent purification bottlenecks arising from excess reagent carryover. The carboxylic acid is pre-activated with propylphosphonic anhydride (T3P, 50 wt% in ethyl acetate) at −20 ± 5 °C in a 50:50 v/v THF/EtOAc mixture, applying a controlled dose of 1.05–1.15 equivalents relative to the amine nucleophile; the narrow excess range is critical because residual T3P-derived byproducts form stable emulsions during aqueous workup, and excess Boc-amino acid partitions into the organic layer, necessitating additional 5% NaHCO3 washes that risk epimerization at the proline C2 position. Process analytical technology (PAT) probes monitor reaction progression via FTIR detection of the 1680 cm⁻¹ carbonyl stretch of the mixed anhydride, with a target endpoint of <1% residual amine chromatographic area by UPLC (sub‑2 µm column, 214 nm). Agitation in a glass-lined 1000 L reactor with turbidity feedback and a three-blade retreat-curve impeller is maintained at 120–150 rpm to ensure uniform heat transfer because the activation exotherm can exceed 45 °C/min without adequate cooling. After coupling, the Boc-protected amide is directly crystallized from n-heptane/2-propanol (85:15 v/v) by controlled cooling at 0.2 °C/min from 60 °C to 5 °C; seeding with micronized product crystals at 40 °C yields a d₉₀ particle size of 120–180 µm as measured by laser diffraction (Malvern Mastersizer). The downstream manufacturing process for the final active pharmaceutical ingredient is governed by ICH M7 limits for mutagenic impurities (acceptable intake 1.5 µg/day for the coupling activators) and ICH Q3C residual solvent thresholds (ethyl acetate <5000 ppm, n-heptane <1060 ppm). The terminal product type is a macrocyclic (4R)-methylproline-bearing acylsulfonamide intermediate suitable for final deprotection and salt formation in class ISO 8 cleanrooms, resulting in an antiviral API for chronic HCV genotype 1b therapy.Asymmetric Ligand Scaffold: Converting (2S,4R)-Boc-4-Methylpyrrolidine-2-Carboxylate to Bidentate Phosphine LigandsReduction of the carboxylic acid functionality with borane-dimethyl sulfide (BH3·SMe2) in anhydrous THF at 0–5 °C yields the corresponding β-amino alcohol after quenching with 1 M HCl in methanol and subsequent Boc deprotection with 4 M HCl in dioxane; the liberated secondary amine is then alkylated or phosphinated directly using chlorodiphenylphosphine (1.0–1.1 eq) in the presence of triethylamine as acid scavenger in a glovebox under argon with <0.5 ppm O2 and <1 ppm H2O, compliant with ASTM D2573-15 for inert atmosphere integrity. The phosphine product serves as a chiral bidentate ligand for rhodium-catalysed asymmetric hydrogenation of prochiral enamides to chiral β‑amino acids, operating at substrate-to-catalyst ratios (S/C) of 500–5000 under 4–8 bar H2 at 25–50 °C. Elemental impurity control follows ICH Q3D Class 1 and 2A limits, with special attention to residual palladium (<10 µg/g) and rhodium (<5 µg/g) measured by ICP-MS after microwave digestion, while ³¹P‑NMR at 202 MHz confirms absence of phosphine oxide impurities (≤0.5 area%). During scale-up to 500 g batches, exothermic phosphine formation requires jacketed borosilicate reactors with −25 °C capability, and the phosphine ligand’s air sensitivity mandates continuous nitrogen purge until formation of the metal complex. The terminal output is a C₂-symmetric diphosphine ligand (e.g., a Josiphos-type derivative possessing the (2S,4R)-pyrrolidine backbone) integrated into a catalyst kit used for enantioselective hydrogenation of β-keto esters in generic drug manufacturing under ISO 13408-1 aseptic processing guidelines where required.Analytical reference standard qualification programs for (2S,4R)-1-[(tert-butoxy)carbonyl]-4-methylpyrrolidine-2-carboxylic acid at >99.5% purity (by HPLC area normalisation at 210 nm) are the cornerstone of pharmacopoeial compliance and in-house impurity profiling for regulatory filings under ICH Q6A. A primary stock solution of 1.0 mg/mL is prepared gravimetrically in 50:50 acetonitrile:water on a six-place analytical balance and serially diluted to 0.01–0.1 mg/mL for system suitability testing per USP <621> and Ph. Eur. 2.2.46, evaluating resolution between the (2S,4R)‑isomer and the (2R,4S)‑enantiomer (minimum Rₛ ≥ 2.0 on a chiral amylose tris(3,5-dimethylphenylcarbamate) column, 250 × 4.6 mm, 5 µm). Production-scale purification is performed using preparative supercritical fluid chromatography (SFC) with a 30 mm I.D. column and CO₂/methanol (85:15) at 120 bar backpressure and 35 °C, achieving throughput of 15 g/h with >99.9% chemical purity. Subsequent lyophilisation in a −80 °C condenser tray dryer at <0.05 mbar for 48 h delivers a crystalline hemihydrate reference material that is dispensed into 10 mg amber vials under class ISO 5 laminar flow in accordance with ISO 17034 and ISO Guide 35, including certification of mass fraction with expanded uncertainty (k=2) below 0.3%. The qualified standard is deployed in finished drug product release testing to quantify process-related (2R,4S)‑enantiomer impurities and des‑Boc degradant (4-methylproline), directly supporting ANDA or MAA stability sections and impurity threshold justifications under ICH Q3A reporting limits of 0.10%. |
Competitive (2S,4R)-1-[(Tert-Butoxy)Carbonyl]-4-Methylpyrrolidine-2-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Method | Acceptance Criterion | Typical Value |
|---|---|---|---|
| Appearance | Visual inspection | White to off‑white crystalline powder | White |
| Purity (HPLC) | USP <621>; C18, 210 nm | ≥ 98.0 area% | 99.2 area% |
| Diastereomeric excess | Chiral HPLC (Chiralpak IA‑3); heptane/EtOH/TFA 90:10:0.1 | ≥ 99.0 % | 99.8 % |
| Water content | USP <921>; Karl Fischer coulometry | ≤ 0.3 % | 0.11 % |
| Residue on ignition | USP <281>; 600 °C | ≤ 0.1 % | 0.03 % |
| Heavy metals (total) | ICP‑MS after microwave digestion; USP <233> | ≤ 10 ppm | 2 ppm |
| Solubility (DCM, 25 °C) | Gravimetric method; 0.1 g·mL⁻¹ test | Clear solution within 5 min sonication | Complies |
| Building Block | Conversion (LC‑MS) | Epimerisation at Pro Residue | Isolated Yield After Flash Chromatography |
|---|---|---|---|
| Boc‑L‑proline | 98 % | <0.1 % | 92 % |
| Boc‑(2S,4R)‑4‑methylproline (title product) | 96 % | 0.15 % | 89 % |
| Boc‑(2S,4S)‑4‑methylproline | 87 % | 3.2 % | 75 % |
| Boc‑cis‑4‑hydroxy‑L‑proline | 94 % | 0.3 % | 85 % |